Navigation Links
Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations
Date:4/8/2009

AMSTERDAM, April 8 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma reported preliminary clinical data on ATIR(TM) showing its potential in mismatched bone marrow transplantations. Data was presented by the company's principal investigator Dr. Denis Claude Roy during the prestigious Presidential Symposium at the Annual European Bone Marrow Transplantation meeting (EBMT) in Goteborg, Sweden, on Monday, March 30, 2009. Only the 6 highest ranked presentations, representing the most promising new developments in the transplantation field, were selected for this Symposium.

ATIR(TM), a donor lymphocyte cell based preparation depleted of allo-reactive T-cells, is under development to prevent acute Graft versus Host Disease (GvHD) and allow for early immune reconstitution following a bone marrow transplantation with a fully mismatched (haplo-identical) donor.

Dr. Roy's presentation of clinical results from 19 end stage blood cancer patients with high risk leukemia and/or lymphoma using ATIR(TM) was very well received. These patients, each of whom did not have a matched donor available, were treated in a phase I/II dose escalating study with ATIR(TM) in a mismatched transplantation setting. No immune suppressants were used, which is in contrast to conventional transplant procedures. Nevertheless, no cases of severe grade III/IV acute GvHD occurred after ATIR(TM) infusion. Furthermore, the clinical data showed a reduction in the frequency of infectious episodes in the cohorts treated with the higher doses of ATIR(TM), as compared to the low dose cohorts. To date, patients in the higher dose cohorts show high survival rates (75%) with no transplant related mortality (TRM).

These results show that the selective depletion of allo-reactive T-cells in the ATIR(TM) cell based product by the proprietary photo-sensitizing agent TH9402 is highly effective and can result in fast and adequate immune reco
'/>"/>

SOURCE Kiadis Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer
2. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
5. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
6. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
7. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
8. Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft
9. New Pharmaxis Board Appointment
10. Pharmaxis Investor Conference Call
11. Gemin X Pharmaceuticals Selects and Deploys Clinical Force CTMS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... June 26, 2015  A San Francisco company, Pembient, ... with synthetic rhino horn: beer in China ... . In response to the emerging industry, two ... and sale of synthetic rhino horn.  ... Save the Rhino International (SRI) released a ...
(Date:6/26/2015)... , ... June 26, 2015 , ... ... services and a subsidiary of OraSure Technologies, Inc. (Nasdaq: OSUR) today announced that ... as part of its Gut Microbiome Grant Program. The company has awarded its ...
(Date:6/25/2015)... 25, 2015 ... announced the addition of the  "2015 ... Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, ... Commercial Labs, POC Locations"  report ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , A ...
(Date:6/25/2015)... June 25, 2015  BioMed Realty Trust, Inc. (NYSE: ... ILMN ), a world leader in genomics focused ... the genome, has signed a 20-year lease for a ... in Cambridge, England . The project ... the highly skilled workforce in the dynamic research cluster ...
Breaking Biology Technology:Rhino Experts Oppose Synthetic Rhino Horn as Solution to Poaching Crisis 2DNA Genotek Inc. Announces Recipients of Gut Microbiome Grant Program 2DNA Genotek Inc. Announces Recipients of Gut Microbiome Grant Program 3Analysis of the Global Cancer Diagnostics Industry 2015-2020: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains 2Analysis of the Global Cancer Diagnostics Industry 2015-2020: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains 3BioMed Realty And Illumina Announce New Build-To-Suit Laboratory Building In Cambridge's Growing Life Science Cluster 2BioMed Realty And Illumina Announce New Build-To-Suit Laboratory Building In Cambridge's Growing Life Science Cluster 3
... Small Companies In America, UNION CITY, Calif., Oct. ... products company manufacturing point-of-care,blood chemistry analysis systems, announced today ... named "Entrepreneur of,the Year" by Forbes Magazine in its ... ranked eleventh of the "200 Best Small Companies in,America." ...
... Held by GlaxoSmithKline Since June 2006, PHILADELPHIA ... The Thomson Corporation (NYSE: TOC ; TSX: ... worldwide research and,business communities, today announced the availability ... on drugs and therapies. "Who is,Making the Biggest ...
... AURORA, ON, Oct. 15 /PRNewswire-FirstCall/ - Helix BioPharma Corp.,(TSX: ... F. McElroy,has resigned as Chairman and a director of ... had a long involvement with the Company since its,amalgamation ... "On behalf of the Company, I thank him for ...
Cached Biology Technology:Abaxis CEO Clint Severson Named 'Entrepreneur of the Year' by Forbes Magazine 2Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007 2Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007 3Helix BioPharma Chairman resigns 2
(Date:6/23/2015)... , June 23, 2015   Valencell, ... the results of a recent study that illustrates ... the wrist during activity. In a study conducted ... compared along with the Apple Watch against a ... heart rate during activity. The study demonstrated that ...
(Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland , ... ®   Produktlinie mit DNA-Tests verbessert ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... neue STR-Testkits der Produktlinie Investigator ® ... den Markt eingeführt. Die neuen Kits zur Erstellung genetischer ...
(Date:6/16/2015)... QUEBEC CITY , June 16, 2015 /CNW ... announce their partnership centralized around the incorporation of ... mobile point-of-care diagnostic laboratory, the Mo-POD™. This unprecedented ... the BIO International Conference at the ... from June 15 th to ...
Breaking Biology News(10 mins):Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3
... 2011 (Rome, Italy) -- Researchers speaking in the second ... Pathogenesis, Treatment and Prevention (IAS 2011) have today provided ... and alerted delegates to the challenges that developing countries ... antiretroviral therapy (ART) coverage. The presentations reflect the ...
... Small-scale fisheries could pose a more serious threat to ... University of Exeter, published today (19 July) in the ... shows that tens of thousands of turtles from across ... small-scale fisheries. Focusing on fisheries in Peru, the ...
... use various appendages to move across surfaces prior to ... jerky form of movement known as "twitching" motility, which ... called type IV pili, or TFP. ... a professor of bioengineering and of chemistry and biochemistry ...
Cached Biology News:Plenary speakers address challenges in the delivery of sustained antiretroviral therapy in developing countries, call for social scientists to take their place at the HIV/AIDS policy-making table, and stress the need for a long-term response to AIDS 2Plenary speakers address challenges in the delivery of sustained antiretroviral therapy in developing countries, call for social scientists to take their place at the HIV/AIDS policy-making table, and stress the need for a long-term response to AIDS 3Study shows small-scale fisheries' impact on marine life 2UCLA study shows bacteria use Batman-like grappling hooks to 'slingshot' on surfaces 2
... The Neural Stem Cell Expansion Kit - Neurosphere ... neural stem cell expansion as neurospheres in ... specially formulated N-2 Plus Media Supplement, which has ... K.K. et al . (1996) Genes & ...
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
... E. coli strain containing an overproducing clone ... Reverse Transcriptase catalyzes the polymerization of DNA ... Full-length copies of large mRNAs, >10 kb, ... a much lower RNase H activity than ...
... RQ1 RNase-Free DNase is a preparation ... or double-stranded DNA to produce 3-hydroxyl ... use in applications where maintaining the ... DNase is qualified for use with ...
Biology Products: